NEW YORK, April 12 - Zyomyx and Axon Instruments have agreed to jointly develop scanning instrumentation for acquiring and analyzing data from Zyomyx's protein biochips, the companies said Thursday.
Zyomyx, which has said it plans to release a beta version of its chip later this year, will work with Axon to build several generations of scanning products and evaluate fluorescence and non-fluorescence platforms. The companies did not disclose financial details.
"Zyomyx strongly impressed us with their advanced protein biochip technology, so we're pleased that they have chosen Axon to co-develop biochip scanning and imaging platforms," said David Wellis, Axon's vice president of functional genomics, in a statement. "The collaboration with Zyomyx is an important part of Axon's strategic plan to expand our functional genomics product line into proteomics."
Based in Hayward, Calif., Zyomyx is developing high density protein chips using a unique surface chemistry derived from high resolution microscopy. The company also has alliances with Cambridge Antibody Technology, Dyax, Fujirebio, and MDS Proteomics.Axon is a Union City, Calif.-based company that develops instrumentation for the neuroscience, neurosurgery, and genomics research markets.